DRP Journal

Discover Research Profit

Finance 

Biostage (OTCMKTS:BSTG) Stock On Radar After a New Appointment

Madison Hall , , , ,

Cell therapy biotech firm Biostage (OTCMKTS:BSTG) is best known for being the first company to have an in-human treatment for esophageal cancer. In fact the company also got the approval from the United States Food and Drug Administration to begin the clinical trial of its Biostage Esophageal Implant.

Trading Data

On Monday, BSTG stock slid 1.14% to $6.08 with 200 shares, compared to its average volume 1.82K shares. The stock moved within a range of $6.05 – 6.08 after opening trade at $6.05.

Biostage Appoints Ron Packard to Board of Directors

However, yesterday the company came on to the news cycle after it announced that it had appointed Ron Packard as an independent director in its Board of Directors. It was a significant new appointment for the company since Packard was going to bring in significant experience in the fields of influence, strategy and innovation.

At this point in time Packard serves as the founder and Chief Executive Officer of the worldwide technology powered education company Pansophic Learning. He is regarded as a visionary entrepreneur and educator, who is also credited for having authored the widely regarded education related book Education Transformation.

In the past he had been the Chief Executive Officer of K12 Inc for a long time and in fact, he is also credited for being the founder of that company. That company eventually went on to rake in revenues of almost one billion from being nothing more than an idea.

Madison Hall

After graduating from the University of Buffalo, Madison gained a real interest in the markets. She tends to be a swing trader and enjoys Pilates and yoga in her downtime.